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The effects of nifedipine, a potent calcium antagonist, were studied in 
patients with unstabie angina, coronary spasm and myocardiai ischemia. 
Data from two separate groups of patients studied in the cardiac cathe- 
terization laboratory indicate that intracoronary injection of nifedipine 
promptly reversed coronary spasm-whether provoked or spontane- 
ous-in five of stx patients in other patients, direct intracoronary inJection 
of the drug was compared with intravenous administration. After intra- 
coronary injection, iocai mechankai cardiac action virtuaiiy ceased, and 
the ventricular wail became thinner during systoie. Thus, a specific in- 
hibitory action on contractile energy expendtture could be demonstrated 
in the presence of increased coronary flow. This “oxygen-sparing” effect 
was tested in a group of 31 patients with symptomatic unstabie angina 
whose pain at rest, with ST-T changes, had not responded to 8 hours of 
treatment wtth maximai beta adrenergic bkckade, nitrates and bed rest. 
The addition of 6 X 10 mg of nifedipine rendered 27 of these patients 
asymptomatic within 1.5 hours. in the four patients who did not respond, 
coronary arteriography demonstrated severely stenotic iesions. Two of 
the four patients subsequently responded to intraaortic balloon pumping 
and bypass surgery; one patient had a myocardtai infarction and one who 
hedagopercentreductioninthedlameteroftheleltmalncoronaryartery, 
died. 
It is concluded that nifedlpine should be added to beta adrenergic 
blockade therapy if the latter does not appear to be hmnediatety effective. 
This combination has not been shown to cause any hemodynamic dete- 
rkratkn, and oniy a mtnority of the patients treated sustained a myocardiai 
infarction during the first 3 months of follow-up. The use of nifedipine in 
unstabie angina deserves further clinical evaluation. 
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The concept that coronary vasospasm is one cause of angina pectoris and 
myocardial infarction has recently been rediscovered, almost a century 
after the original descriptions by Latham.’ In fact, in the past few years, 
several investigators2-7 have brought about a shift in attitude concerning 
the pathophysiologic derangements underlying myocardial infarction. 
It is now accepted that temporary obliteration of coronary blood flow 
due to increased vessel wall tone, even in the absence of fixed coronary 
arterial obstruction and stenosis, can lead to myocardial infarction. Most 
likely, intermittent and fixed coronary stenosis act in combination; that 
is, increased vasomotility of a major vessel around a fixed obstruction 
causes the critical reduction in flow that leads to irreversible ischemia. 
To what extent platelet aggregates and disturbances in prostaglandin 
metabolism play a role is as yet unclear, but their effects may well be 
additive. 
Such a view opens new avenues for treatment because, if coronary 
spasm or increased vascular tone can be recognized, timely relief of the 
condition should reverse the process of impending infarction. Our cur- 
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BeFORE INTlkRVENTION 
mean diameter 15.8 units 
l”&Ln“AFTER 0.4mg METHERGlNE l.V, 
3 min AFTER 0.4 mg METHEkGlNE I.V. 
1 min AFTEk 0.2 mg NIFEDIPINE I.C. 
mean diameter 21.5 units 
FlQlJRE 1. Patient I (Table I). Four frames from a cineangiogram. Upper Iaft, the involved right cwonary artery before intervention. Lower Ielt and 
uppsr w spasm provoked by an intravenous (I.V.) injection of metfwgine (ergonovine). Note that in the upper rf@l frame the artery has virtually 
“diT@“. LOWW right, abolition of the spasm by intracoronaty (l.c.), injection of nifedlpine. Simultaneously recorded electrocardiograms 
(leads I. II and Ill) are shown An automated measurement system was employed to gada changes In the caliber of the ri@t corcnary artery @ottan) 
which Is expressed in units reflecting a surface ~~88.‘~ 
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study relates to several experiences that provide 
a partial answer to the potential efficacy of nifedipine 
in this scheme of events. First, nifedipine’s powerful 
action as a calcium antagonist leads to vessel dilation, 
which has proved effective in classic Prinzmetal’s angina 
in which spasm is known to be the main causative 
mechanism. Direct intracoronary injection of nifedipine 
has been observed to lead to prompt restoration of the 
normal caliber of a totally occluded vessel. 
However, other actions of nifedipine may make this 
drug equally attractive for the treatment of patients 
with unstable angina pectoris. In our laboratory, mea- 
surements of left ventricular function, both in pigs and 
in human subjects, have shown that local mechanical 
contraction ceases for up to 5 minutes when nifedipine 
is injected into the coronary artery supplying the isch- 
emit cardiac muscle. In patients with unstable angina, 
the best protective action for ischemic cells might be 
provided if coronary flow could be increased and local 
consumption of oxygen simultaneously decreased, while 
electrical activation continued normally. 
To test these hypotheses, we studied a group of pa- 
tients admitted to the coronary care unit with angina 
pectoris at rest and transient S-T segment or T wave 
changes but without evidence of acute myocardial in- 
farction, such as abnormal enzyme release and devel- 
opment of Q waves. At our center, this high risk group 
of patients with unstable angina is routinely managed 
with bed rest and administration of oxygen, sedatives, 
long-acting nitrates and beta adrenergic blocking 
agents. The therapeutic objective is to return the patient 
with signs of myocardial ischemia to a stable and 
asymptomatic state, thereby preventing infarction. In 
our hands, this regimen has not proved successful in all 
patients. In fact, until recently it was our policy to 
proceed to emergency coronary bypass surgery (in 
several cases with prior intraaortic balloon pumping) 
when no relief was obtained after 8 to 12 hours of max- 
imal therapy with beta adrenergic blocking agents8 
Study 1 
Methods 
The methodology employed for the animal data quoted 
under Results has been published elsewhere and will not be 
repeated here. 
For the first part of the clinical study, data were collected 
from 6 patients who underwent cardiac catheterization be- 
cause of myocardial &hernia suspected to be secondary to 
spasm and from 10 other patients who have had bypass sur- 
gery 1 year before catheterization. In the latter group, a total 
of 26 pairs of radiopaque platinum markers had been im- 
planted on the epicardium at operation. Seventeen of these 
marker pairs (in 10 patients) were placed on areas newly 
supplied by blood from the coronary arterial bypass graft, and 
nine pairs of markers (in 9 patients) were placed in areas not 
supplied by the coronary arterial system. 
Patients with coronary spasm: Of the six patients with 
suspected coronary arterial spasm, two showed the full- 
fledged clinical syndrome of Prinzmetal’s angina. During 
catheterization, spontaneous spasm was observed in three of 
the six, and in another two spasm was induced by intravenous 
injection of methergine (an ergot alkaloid similar to ergono- 
vine). In the sixth patient, spasm was induced during ma- 
nipulation of the catheter. In each patient, as soon as spasm 
was observed, the average dose of nifedipine (2 yglkg body 
weight) was selectively injected into the coronary artery in 
spasm and biplane filming was performed (Fig. 1, Table I). 
This average dose had been selected as a result of previous 
studies in our laboratory.g No effort was made to test the pa- 
tient’s response to nitrates before administration of nifedi- 
pine. 
Patients after coronary bypass surgery: During re- 
catheterization of 10 postoperative patients a pacing catheter 
was placed into the right atrium (Fig. 2). Heart rate was fixed 
at 10 beats above the spontaneous rate present before the 
pharmacologic intervention, Left ventricular pressures were 
recorded with a double micromanometer (Millar PC770 or 
780). The methodology for measuring regional shortening 
from epicardial radiopaque markers has been described in 
detail elsewhere.lO In brief, the radiopaque marker pairs im- 
planted in the epicardium at operation are filmed during 
synchronized biplane cinefluoroscopy at 50 frames/s. The 
absolute distances between each marker pair are calculated, 
with five consecutive heart beats being analyzed as a control 
set before intrabypass injection of nifedipine and again 30,60, 
120 and 180 seconds after the injection. During this period, 
variables derived from left ventricular pressure measurements 
are monitored continuously by means of the beat to beat 
analysis program of our cardiac catheterization laboratory 
computer.l’ Pressures were recorded for a period of 5 minutes 
before and during the injection of nifedipine. End-diastolic 
pressure, peak systolic pressure, peak positive first derivative 
of left ventricular pressure (dP/dt), cycle length, peak velocity 
of contractile elements (Vce) and maximal velocity of con- 
tractile elements (Vmax) were derived by means of the on-line 
computer program. In addition, an analysis of the isovolumic 
relaxation phase was carried out by calculating the peak 
negative dPldt. The relaxation time constant was determined 
by a least-squares fit of a monoexponential equation de- 
scribing the fall of left ventricular pressure from the moment 
TABLE I 
Arteriographlc Flndlngs and Effect of Nifedipine in Six 
Patients With Either Spontaneous or Induced Coronary 
Arterial Spasm 
Case Spasm 
Arteriographic 
Findings 
(vessel and lntracoronary Intravenous 
% obstruction) Nifedipine’ Nitroglycerin’ 
1 Methergine- RCA + 
induced (100%) 
2 Methergine- 
induced 
3 Spontaneous 
4 Spontaneous 
5 Catheter- 
induced 
6 Spontaneous 
+ 
+ . 
+ 
+ . . 
+ . . 
* Immediate administration of intracoronary nifedipine relieved the 
obstruction completely in five of six patients; intravenous nitroglycerin 
proved effective in one. 
LAD = left anterior descending coronary artery: LCx = left circumfiex 
coronary artery; RCA = right coronary artery: -I- = effective; - = not 
effective; . . . = not administered. 
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FIGURE 2. Diagram of the principal methods employed 
in the study. See text and Reference 10 for details on the 
- FlL” SPEED: 50 FRAMES/SEC measurement of regional shortening with radiopaque 
- FILMS BEFORE NIFEDIPINE AND 30. markers attached to the epicardium during coronary by- 
60,120,180, MO 300 SEC AFTER N. pass surgery. LAO = left anterior oblique; LV = left 
- P”R&T,ON OF EKH FILM: 5 BE&TS ventricular; N. = nifedipine; RAO = right anterior 
oblique. 
of peak negative dPJdt to that existing at a pressure of 35 mm were often elevated but in no instance reached values 
Hg (Fig. 3). twice the normal in our laboratory. 
Study 2 
Patients with unstable angina: The second part of 
the study, was carried out between June 1, 1979 and 
January 1, 1980, when 720 patients with various 
symptoms of coronary artery disease were admitted to 
our coronary care unit. Forty-seven of these patients 
had precordial pain at rest that was typical of angina 
pectoris and that persisted or worsened. In all 47 pa- 
tients, transient ST-T changes but no new & wave for- 
mation were documented in the coronary care unit 
during angina at rest. The patients’ serum enzyme levels 
On admission, all patients were placed in a private 
room, although they remained directly accessible to the 
nursing staff. Hemodynamic monitoring was initiated 
immediately by means, of a Swan-Ganz thermodilution 
catheter advanced from the subclavian or right jugular 
vein or an arm vein into the pulmonary artery. If either 
hypotension or hypertension was present initially, a 
catheter was inserted into the left radial artery with use 
of local anesthesia. All patients received heparin in- 
travenously (30,000 units or less every 24 hours). A 
semiautomated monitoring system facilitated contin- 
uous recording of heart rate, cardiac rhythm and pul- 
LVP , mmHg 
FIGURE 3. lsovolumic variables, as determined by the 
beat to beat analysis program of the catheterization 
laboratory computer system. dP/dt = rate of rise of left 
ventricular pressue; EDP =: eMdiastOliC presswe; LVP 
= left ventricular pressure: P = 35 = pressure at 35 mm 
f-fg;P-_eATfsr the constant and intercept of the re- 
gression line: Pk = peak; TCR = time constant for ra 
laxation determined by slope (A) of pressue on log-linear 
plot; v, = velocity of contractile elements; V, = 
maximal velocity of contractile elements. 
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monary arterial pressure, while systemic blood pressure 
and cardiac output were determined at regular intervals. 
During and after every attack of pain, a 12 lead elec- 
trocardiogram was recorded, and if pain persisted, the 
recording was repeated at 15 minute intervals. On ad- 
mission and 6 hours after each attack of pain, creatine 
kinase, MB-creatine kinase and n-HBDH cardiac en- 
zymes were measured. 
After initial sedation, usually with oral diaxepam (5 
to 10 mg three times daily), the patient was given iso- 
sorbide dinitrate, 5 mg every 2 hours sublingually or, if 
necessary, intravenously. In addition, propranolol was 
administered intravenously at doses ranging from 1 to 
10 mg until a heart rate of 60 beats/min was reached. 
Thereafter, propranolol was given orally at doses 
ranging from 400 to 800 mg every 24 hours. When pro- 
pranolol was contraindicated, as in patients with lung 
disease, a cardioselective beta adrenergic blocking agent 
was chosen. 
The 47 patients studied included 38 men and 9 
women aged 29 to 77 years (mean 58). Three subgroups 
of patients could be identified: Twelve (group I) had no 
history of previous coronary artery disease, 25 (group 
II) had a history of long-standing coronary artery dis- 
ease and the remaining 10 (group III) had a return of 
angina at rest within 2 weeks after discharge from the 
hospital where they had been treated for an acute 
myocardial infarction. Two patients in group II and one 
in group III had previously had coronary bypass 
grafting. 
Results 
Nifedipine injection into coronary bypass graft: 
Data collected from the patients studied during cardiac 
catheterization are shown in Tables I and II and Figures 
4 and 5’2 After direct injection of nifedipine into the 
coronary graft bypass the expected reduction in peak 
left ventricular systolic pressure occurred. There was 
also an increase in end-diastolic pressure as well as a 
marked decrease in peak positive dP/dt, peak negative 
dP/dt and V,,,, and an increase in the relaxation time 
constant. All of these differences were statistically sig- 
nificant when compared with control measurements. 
FK#IRE 4. b&xmalized shwtenirtg fraction during ejectkm 
in selective regions as determined by movement of ra- 
diopaqua markers (direct (d], n = 17) and independentfy 
perfused marker pa& regions (indirect [i] , n = 9). Values 
shown are relative changes from control values. Within 
30 seccn& of injecticn of nifedlpine into ths bypass graft 
a large and significant decline in the regional ejection 
fraction of the myocardium perfuM by the bypass graft 
occurred (direct region) and recovery occurred rapidly; 
this was accompanied by only a small reduction in the 
localized ejection fraction of the myocardium not per- 
fused by the graft. 
TABLE II 
Pressure-Derived Variables After lntracoronary Bypass 
Injection of Nifediplne (10 injections, mean f standard 
error of the mean) _____ -_-----_-- 
Control 
Value Peak Effect 
Peak LVP (mm Hg) 141 f 8 124 f 7’ 
EDP (mm fig) 16 f 2 264~3’ 
Peak positive dP/dt (mm fig/s) 1855 f 118 1521 f 73’ 
V,(iengths/s) 55 f 3 434 2’ 
Peak negative dP/dt (mm IQ/s) 2133 f 135 1575 f 86’ 
Negative dP/dt at 35 mm Hg (mm Hgls) 873 * 43 598 f 53’ 
Relaxation time constant flenothsls) 39 f 2 54f3’ 
l p < 10-S. + p < 10-4. 
dP/dt = rate of change of left ventricular pressure; EDP = enddia- 
stolic pressure; LVP = left ventricular pressure; V,, = maximal ve- 
locity of contractile elements. 
The shortening fraction during ejection, that is, the 
systolic phase of the cardiac cycle, was markedly de- 
creased in the area directly perfused by the artery inbo 
which nifedipine had been injected (Fig. 4 and 5); in 
contrast, no changes were observed elsewhere in the 
heart. The onset of regional shortening was delayed and 
the shortening rate was diminished. Minimal length was 
shifted from end-systole to early diastole, as if con- 
traction had continued during diastole. 
These responses were previously observed in exper- 
imental animals in which regional wall thickness and 
blood flow in the left anterior descending coronary ar- 
tery were measured in areas perfused by this artery after 
nifedipine was injected directly into it (Fig. 6A).g The 
difference between coronary arterial and pulmonary 
arterial infusion is shown in Figure 6. All changes in left 
ventricular variables were transient, and function re- 
turned to control levels within 5 minutes. All measure- 
ments were made at a constant rate of pacing, and direct 
slowing of contraction and relaxation must be in- 
ferred. 
Oral nifedipine in unstable angina (Fig. 7): Six- 
teen of the 47 patients with unstable angina who were 
treated with propranolol or other beta blocking agents 
indirect r - - - - 
pi 0.001 
0.6 
control 30s 60s 120s 180s control 2 
-c time 
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NDIRECT (n-9) 
E$ 
and nitrates became asymptomatic 3 to 8 hours after the 
onset of treatment. Of the other 31 patients who, in 
addition, received oral nifedipine in doses of 10 mg six 
times a day, 27 became asymptomatic within 1.5 hours 
and remained so for the remainder of their hospital stay; 
4 patients did not respond to nifedipine. Two of these 
sustained a myocardial infarction within 24 hours, and 
one died. Because of persistent pain, two other patients 
underwent intraaortic balloon pumping, with imme- 
diate relief of symptoms. s Both underwent coronary 
bypass grafting and both are alive. Coronary arteriog- 
raphy showed that three of these four patients had more 
than 75 percent obstruction in three vessels, while the 
fourth patient, a 73 year old man, had 90 percent ob- 
struction of the left main coronary artery and had a fatal 
myocardial infarction shortly after coronary arteriog- 
raphy. 
Twenty of the 27 patients who experienced initial 
relief of symptoms when nifedipine was added to the 
therapeutic regimen underwent elective coronary ar- 
teriography and left heart catheterization after they 
resumed some degree of physical activity in the inter- 
mediate care unit. However, one patient with postin- 
farction angina (group III) sustained a fatal myocardial 
infarction before catheterization and within 7 days of 
initiation of nifedipine treatment. Of the 19 patients 
undergoing catheterization, 1 had greater than 90 per- 
cent cross-sectional obstruction of the left main coro- 
nary artery and 9 had three vessel, 3 had two vessel and 
six had one vessel coronary artery disease with greater 
than 75 percent obstruction. 
Follow-up: In addition to the patient with fatal in- 
farction, four other patients had a nonfatal infarction 
within 2 weeks after the initial relief of symptoms. In 
two of these patients, the event was related to angiog- 
raphy; both had extensive pain, with ST-T changes and 
a slight rise in cardiac enzyme levels but without new 
Q wave formation. In one of the other two patients 
coronary arterial spasm was documented during angi- 
FKXRE 5. Regkmal shortening measured with 
pairs of radiopaque markers in (left) region of 
myocardium into which nifedipine had been 
injected (direct, n = 17) and (rfght) otfw re- 
gions of myocardium (indirect, n 5 9). From 
top to bottom: Control period and 30,60,120, 
and 180 seconds after intrabypass injection of 
nifedipine. The shaded area represents the 
shortening pattern of the first control period. 
In selectively injected regions, the onset of 
regional shortening (L,,& is delayed, the 
shortening rate is diminished, and L,,,rn is 
shifted from end-systofe to early diastole. EDP 
= erddiastolic pessure; EJ = ejection; ES = 
end-systole. Left panel reproduced from Ser- 
ruys et al. ‘* by permission of the American 
Heart Association, Inc. 
ography and injection of nifedipine into the involved 
coronary artery led to immediate relief. 
Thus, of the total group of 27 patients who were 
managed with nifedipine and who became asymptom- 
atic, 5 sustained an infarction (fatal in 1) within 2 weeks 
after initial stabilization. During further follow-up (3 
to 5 months) no other instances of myocardial infarction 
were noted. Thus far, 15 of the 19 patients who under- 
went catheterization have undergone elective coronary 
bypass grafting. In these patients, the indication for 
operation consisted of a past history of unstable angina 
and an advanced degree of coronary arterial stenosis. 
All are alive and well. The other 11 patients have re- 
mained asymptomatic and have been maintained on 
nifedipine therapy. 
Discussion 
Effect of nifedipine on coronary spasm and on 
myocardial contraction (local contractile arrest in 
presence of increased coronary flow): The two parts 
of this study were carried out in patients with proved 
or suspected coronary arterial spasm. From the data in 
Table I, there is little doubt that in the majority of pa- 
tients, direct intracoronary injection of nifedipine yields 
prompt relief when spasm can be demonstrated. Other 
authors,2-6 using a variety of techniques, have demon- 
strated that this calcium blocking agent has a similar 
beneficial action. In addition, the data shown in Figures 
4,5, and 8 indicate that locally administered nifedipine 
acts directly on the myocardium. Measurements of the 
changing distances between radiopaque markers placed 
on the epicardium (Fig. 5) indicate that major changes 
in wall motion take place as early as 30 seconds after 
injection of nifedipine. The distance between the 
markers is substantially increased, with a reduction in 
regional shortening to approximately 67 percent of the 
control value. The rate of systolic shortening is signifi- 
cantly diminished, indicating a slowing of the local 
contractile process; the separation between the marker 
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PA infusion LAD infusion 
FIGURE 6. A, tiemodynamic changes after ad- 
ministration of 3 gg/kg of nifedipine into the pul- 
monary artery (PA) and into the left anterior de- 
scending coronary artery (LAD) of the same pig. 
Note that the effects on mean arterial blood 
pressure (MBP) and the rate of fall of left ventric- 
ular pressure (LV dP/dt,& are independent of the 
site of injection, whereas the magnitude of the 
effects on myocardial contractility (peak V,, and 
LV dP/dt,) and ventricular filling pressure 
(LVEDP) are dependent on the site of the injection. 
The heart was paced at 104 beats/min.’ P <0.05 
compared with baseline. B, left anterior de- 
scending coronary arterial (LAD) blood flow (from 
an electromagnetic flowmeter) and myocardial 
wall thickness after administration of 3 pg/kg of 
nifedipine into the pulmonary artery (PA) and the 
left anterior descending coronary artery. Injection 
into the pulmonary artery had no effect, that into 
the left anterior decending artery caused a tran- 
sient decrease, mainly in end-systolic thickness 
(EST). After 3 minutes, a rebound in enddfastolic 
thickness (EDT) was observed (0.5 mm larger than 
baseline value). l p CO.05 compared wlth baseline 
value. 
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Vduntary Apnea 
CORONARV SINUS FLOW 
pairs reaches a minimum 80 ms after closure of the 
aortic valve, indicating that contraction became pro- 
longed; in fact, at the peak of action of nifedipine, 38 
percent of total regional shortening took place during 
early diastole of the ventricle as a whole. None of these 
changes were seen when marker distances were mea- 
sured in the same patient in areas not perfused by ni- 
fedipine. 
These observations complement published results 
from studies performed in our laboratory in the open 
chest pig9 when nifedipine, in a dose of 3 pg/kg, was 
administered over 20 seconds into the left anterior de- 
scending coronary artery (Fig. 6). In these animals, 
coronary arterial flow, measured simultaneously from 
an electromagnetic flowmeter, showed a marked in- 
crease during the first 3 minutes after injection, and 
systolic thickening of the ventricular wall decreased 
from 18 to 11 mm during the same time. In other words, 
end-diastolic thickness decreased, systolic thickening 
was virtually abolished, and the process of contraction 
became extended into what is early diastole for the re- 
mainder of the ventricle. Yet, at the same time, flow in 
the left anterior descending coronary artery increased 
by 40 percent above its control value. None of these 
changes occurred in animals when the same dose of drug 
was infused into the pulmonary artery. 
Similar findings have been documented in several 
patients. Data from one of these patients (Fig. 71, 
measured beat by beat over a period of 300 seconds, 
clearly show the immediate effect of nifedipine on 
ventricular wall dimensions, end-diastolic pressure, and 
FIGURE 7. Continuous plot of 
marker distance (L,, L,+) with 
shortening fraction, left ventricular 
pressures (LVP and EDP), Vmex and 
the relaxation time constant of the 
region perfused by an injection of 
nifedipine into a patent bypass graft. 
In this patient, coronary sinus flow 
was measured continuously. Shortly 
after intrabypass injection of ni- 
fedipine, the shortening fraction 
(SF) decreased from 6.3 to 2.2 
percent, accompanied by a rapid 
rise in end-diastolic pressure and 
decreases in V, and left ventric- 
ular peak pressure. Simultaneously 
coronary sinus flow increased from 
150 to more than 200 mllmin. 
v . Perhaps most important, in terms of the mecha- 
nit: of action of the drug, the relaxation time constant 
increased by some 50 percent. All of these values could 
also be reliably measured during a period of voluntary 
apnea, showing that respiratory influences were mini- 
mal. The effects of nifedipine were maximal 30 seconds 
after injection, at which time the shortening fraction was 
barely 1.6 percent and V,,, was at its lowest, yet coro- 
nary sinus blood flow had increased 200 ml/min. These 
appear to be extremely favorable responses for the 
ischemic myocardium. 
These human and animal experiments complement 
each other and indicate that there is marked local 
contractile “arrest” in the presence of increased COT- 
onary flow. These data also complement hose originally 
presented by Griin and Fleckenstein13 and Vater,l* who 
demonstrated that similar doses of nifedipine led to 
significant reductions in myocardial oxygen consump- 
tion in regions perfused by the coronary artery into 
which the drug had been injected. 
Beneficial effects of nifedipine therapy for un- 
stable angina: This series of observations, indicating 
an “oxygen-sparing” effect of nifedipine, led to our use 
of the drug in patients with unstable angina (Fig. 8 and 
9). Indeed, the hypothesis has been put forward that the 
subset of patients with suspected coronary arterial 
spasm may receive no benefit from beta adrenergic 
blocking agents, and Yasue et a1.4 have specifically ar- 
gued against their use in this group of patients. Rather, 
when beta adrenergic blockade has failed to relieve 
symptoms-despite its reduction of heart rate and 
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SEQUENCE OF EVENTS IN 47 PATIENTS ADMITTED TO THE CCU 
WITH UNSTABLE ANGINA IN WHOM IMPENDING INFARCTION WAS SUSPECTED 
0 47 
Unstable Angina-Angina at rest; 
ST/T changes 
No Cl wave formation 
No increase in enzyme levels 
Treatment with bed rest, 
beta blockade and nitrates 
I 
Asymptc 
I 
Observation CCU for 48 h 
I 
Intermediate Care Unit: 
Later Coronary Arteriography 
%tic 58 h 
Asymptomatic 58 h 
g/24 h added 
Symptomatic >8 h 
Nifedipine 60 ml 
5 
4 
Irnz 
l 
itic >8 h 
Infarction 
-----El 
No infarction 
3 
Dead Urgent CABG 
(2 with IABP) 
FIGURE 8. Schematic view of developments in 47 patients with suspected impending myocardial infarction. CABG = coronary arterial bypass 
grafting; CCU = coronary care unit; IABP = intraaortic balloon pumping. 
THE INTERPLAY OF CAUSES OF ANGINA PECTORIS, 
ARRHYTHMIAS, MYOCARDIAL INFARCTION 
AND SUDDEN DEATH (ZONE m ) 
UNSTABLE ANGINA 
PAIN UPON 
EXERTION 
- 
IMPENDING 
INFARCTION OBSTRUCTION 
SUDDEN 
BY PLATELET 
PAIN WITH 
ARRHYTHMIAS 
IN REST 
(PRINZMETAL) 
DEATH 
MYOCARDIAL 
INFARCTION 
FIGURE 9. Schematic view of the interplay of the three main causes of unstable angina: fixed stenosis of coronary arteries, coronary arterial spasm, 
and coronary arterial obstruction by platelet aggregates. Nifedipine appears to have its most useful application in the hOrlzontaffy hatched 
area. 
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competitive blocking at beta receptor sites-the addi- 
tion of nifedipine, or perhaps the use of nifedipine alone, 
may be the more logical approach. Theoretically, the 
inhibition of transmembrane calcium influx into cardiac 
muscle fibers. results in less phosphate-bound energy 
being transformed into mechanical work by calcium- 
dependent myofibrillar adenosine triphosphate (ATP), 
which in turn leads to a reduction in cardiac oxidative 
metabolism; oxygen need is therefore diminished. In 
addition, the reduction in the calcium-dependent con- 
tractile tone of the larger epicardial coronary arte- 
ries-and perhaps to some extent the capillaries as 
well-indicated by the sudden reduction of ventricular 
wall thickness (Fig. 6B) leads to increased flow and thus 
rapidly restores the regional oxygen concentration to 
normal. In addition to these changes, dilation of large 
peripheral arteries will diminish afterload and may re- 
sult in a further, indirect reduction in cardiac oxygen 
demand. 
Henry et all5 have indicated that even when an area 
around an infarct is rendered ischemic, a reduction in 
the quantity of ischemic cells can be achieved with ni- 
fedipine. In those patients in our group who did not 
respond to beta adrenergic blockade, nifedipine pro- 
duced similar dramatic and sudden results. Although 
this study was not randomized and in many other re- 
spects did not meet the requirements of a strict clinical 
trial, the reduction in symptoms was impressive. 
Twenty-seven of the 31 patients treated with nifedipine 
in addition to beta blocking agents became asymp- 
tomatic within a very short period of time and remained 
so in nearly all instances. Given the brittle clinical state 
of these patients, and the failure of all other supportive 
therapy, it is highly likely that nifedipine was respon- 
sible for the improvement. In fact, in the four patients 
in whom nifedipine did not evoke a similarly favorable 
response, the extent of fixed organic stenosis, as dem- 
onstrated on coronary arteriography, was severe enough 
that the lack of response to a spasmolytic agent was 
hardly surprising. The subsequent response of these 
patients to intraaortic balloon pumping and emergency 
bypass surgery underscores that their obstructive le- 
sions were mainly of an organic nature. Under these 
conditions, the action of nifedipine may well be less 
specific and unique. 
Role of coronary spasm in unstable angina in 
presence of severe atherosclerotic disease: In this 
regard it is of interest to examine the coronary arterio- 
graphic findings in 20 of the 27 patients who responded 
promptly to nifedipine and to discuss briefly the rate 
of myocardial infarction. One patient with postinfarc- 
tion angina died 7 days after admission to the coronary 
care unit, just before the planned catheterization. Au- 
topsy showed extensive three vessel disease, including 
narrowing of the left main coronary artery. As indicated 
earlier, of the remaining 19 patients, 1 had greater than 
90 percent narrowing of the left mainstem, and 9 had 
three vessel disease, 3 had two vessel disease and 6 had 
one vessel disease with more than 90 percent obstruc- 
tion. To date, 15 of these 19 patients have undergone 
bypass grafting and 4 sustained a nonfatal myocardial 
infarction before they could be operated on-in im- 
mediate relation to the cardiac catheterization proce- 
dure in 2 and after discharge from the hospital in 2. The 
15 patients operated on are asymptomatic and no longer 
receive nifedipine therapy; the 11 patients not operated 
on are also asymptomatic but still receive nifedipine 
therapy. 
These findings indicate the presence of severe ath- 
erosclerotic coronary artery disease in 14 of the 20 pa- 
tients studied. It is suggested that the symptoms in the 
remaining 6 patients approximate those of Prinzmetal’s 
syndrome although the complete manifestations thereof 
could not be observed during the acute phase. Because 
of the prompt response to nifedipine, spasm would seem 
to have been the dominant mechanism. In those pa- 
tients with a long-standing history of coronary artery 
disease and severe atherosclerotic disease spasm 
probably played only a secondary role, although it was 
equally responsive to nifedipine. 
Therapeutic failures and occurrence of myo- 
cardial infarction: In the four patients who did not 
respond to nifedipine therapy the rapidity of the sub- 
sequent events suggests that treatment with nifedipine 
had commenced too late. Five of the 27 patients who 
responded to nifedipine nevertheless sustained an in- 
farction in the subsequent weeks compared with 2 of the 
4 nonresponders. Because 1 of the 5 responders had had 
a previous infarction (group III) and in 2 (both from 
group II) the infarction occurred during coronary ar- 
teriography, nifedipine therapy can be considered to 
have failed in only 2 (7.4 percent) of the 27 patients in 
the longer term. This incidence relates favorably to the 
generally quoted incidence of myocardial infarction, 
which ranges from the 13 percent in the Rotterdam 
IMIR studyI to 23 percent reported by Vakil,ls in these 
severely ill patients with impending infarction. Inci- 
dentally, in our study the two responders to nifedipine 
with subsequent infarction had three vessel disease 
during coronary arteriography. 
Therapeutic implications: We believe that nifedi- 
pine should be added to beta adrenergic blocking drugs 
when the latter show no immediate effectiveness in 
patients presenting with angina at rest. The combina- 
tion of nifedipine and a beta blocking agent has not been 
shown to cause any adverse hemodynamic effects. In our 
opinion, nifedipine deserves further clinical evaluation 
for use in unstable angina. 
Nifedipine inhibits myocardial contractility while 
increasing coronary blood flow and this combination of 
actions may help prevent myocardial infarction in pa- 
tients who have unstable angina with a substantial 
vasospastic omponent (Fig. 9). However, those patients 
with advanced fixed organic obstructions do not re- 
spond as well. 
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